Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Recent advances in vaccine development for herpes simplex virus types I and II.

Coleman JL, Shukla D.

Hum Vaccin Immunother. 2013 Apr;9(4):729-35. doi: 10.4161/hv.23289. Epub 2013 Feb 26. Review.

2.

Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown.

Chentoufi AA, Kritzer E, Yu DM, Nesburn AB, Benmohamed L.

Clin Dev Immunol. 2012;2012:187585. doi: 10.1155/2012/187585. Epub 2012 Mar 26. Review.

3.

A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.

Wang K, Goodman KN, Li DY, Raffeld M, Chavez M, Cohen JI.

J Virol. 2015 Nov 11;90(1):562-74. doi: 10.1128/JVI.01845-15.

4.

Vaccines for herpes simplex virus infections.

Koelle DM.

Curr Opin Investig Drugs. 2006 Feb;7(2):136-41. Review.

PMID:
16499283
5.

Developments in herpes simplex virus vaccines: old problems and new challenges.

Rajcáni J, Durmanová V.

Folia Microbiol (Praha). 2006;51(2):67-85. Review.

PMID:
16821715
6.

Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.

Awasthi S, Huang J, Shaw C, Friedman HM.

J Virol. 2014 Aug;88(15):8421-32. doi: 10.1128/JVI.01130-14. Epub 2014 May 14.

8.

Development of prophylactic vaccines for genital and neonatal herpes.

Jones CA, Cunningham AL.

Expert Rev Vaccines. 2003 Aug;2(4):541-9. Review.

PMID:
14711338
9.

Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein.

Reszka NJ, Dudek T, Knipe DM.

Vaccine. 2010 Mar 24;28(15):2754-62. doi: 10.1016/j.vaccine.2010.01.030. Epub 2010 Jan 29.

11.

A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs.

Odegard JM, Flynn PA, Campbell DJ, Robbins SH, Dong L, Wang K, Ter Meulen J, Cohen JI, Koelle DM.

Vaccine. 2016 Jan 2;34(1):101-9. doi: 10.1016/j.vaccine.2015.10.137. Epub 2015 Nov 10.

PMID:
26571309
12.

Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.

Stanberry LR.

Herpes. 2004 Aug;11 Suppl 3:161A-169A. Review.

PMID:
15319086
13.

[Herpes simplex virus vaccine studies: from past to present].

Us D.

Mikrobiyol Bul. 2006 Oct;40(4):413-33. Review. Turkish.

PMID:
17205702
14.

Potential prophylactic and therapeutic vaccines for HSV infections.

Ramachandran S, Kinchington PR.

Curr Pharm Des. 2007;13(19):1965-73. Review.

PMID:
17627530
15.

Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.

Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE, Cohen JI.

J Infect Dis. 2009 Oct 1;200(7):1088-95. doi: 10.1086/605645.

16.

Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice.

El-Ghorr AA, Williams RM, Heap C, Norval M.

FEMS Immunol Med Microbiol. 2000 Dec;29(4):255-61.

17.

The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine.

Kuo T, Wang C, Badakhshan T, Chilukuri S, BenMohamed L.

Vaccine. 2014 Nov 28;32(50):6733-45. doi: 10.1016/j.vaccine.2014.10.002. Epub 2014 Oct 16. Review.

18.
20.

Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease.

Jones CA, Cunningham AL.

Herpes. 2004 Apr;11(1):12-7. Review.

PMID:
15115632

Supplemental Content

Support Center